Arlene Naranjo,
Associate Program Director & Research Associate Professor
Department:
PHHP-COM BIOSTATISTICS
Business Phone:
(352) 273-0577
Business Email:
anaranjo@cog.ufl.edu
About Arlene Naranjo
Dr. Arlene Naranjo is a Research Associate Professor in the Department of Biostatistics and Associate Program Director of the Children’s Oncology Group (COG) Statistics & Data Center (SDC) at the University of Florida. As lead statistician for neuroblastoma with the COG SDC, Dr. Naranjo is responsible for designing future studies, performing sample size and power calculations, monitoring open studies, and analyzing results from pediatric clinical trials. Her research interests include clinical trials design & analysis, survival analysis, longitudinal data analysis, and hierarchical linear models. Dr. Naranjo helped develop and currently co-teaches the graduate-level course Design and Conduct of Clinical Trials.
Accomplishments
Faculty Enhancement Opportunity (FEO) award
2012
·
University of Florida
Teaching Profile
Courses Taught
2018-2023
PHC6022 Design and Conduct of Clinical Trials
2016-2017
PHC6937 Special Topics in Public Health
2016
PHC6601 Seminar in Contemporary Public Health Issues
2016
PHC6946 Public Health Internship
2010-2012,2014-2016
GMS6819 Design and Conduct Clinical Trials II
2011-2015
GMS6818 Design and Conduct Clinical Trials I
Research Profile
My area of specialization is in the design, conduct, analysis, and reporting of results of pediatric cancer clinical trials for patients with neuroblastoma. I have worked for over a decade in this area and my expertise is in clinical trial designs for small patient populations, statistical applications to clinical trials, survival analysis, group sequential methods for assessing early evidence of efficacy and futility, prognostic factor analysis, and biomarker optimal cut-point determination. As a member of the Children’s Oncology Group (COG) Statistics & Data Center (SDC), I have designed and analyzed data from clinical trials ranging from small Phase II and pilot studies with short-term endpoints such as response to large Phase III trials with event-free and overall survival long-term endpoints. In collaboration with COG investigators from all over the world, I have led the statistical effort to identify new molecular targets for development of novel therapies, refine disease response assessment, better understand the genetic basis of neuroblastoma, and share the datasets with academic researchers worldwide to improve our understanding of the pathogenesis of this neoplasm and improve patient outcomes. This work has been funded by the multi-million COG SDC grant and related correlative study grants using annotated banked tumor samples from patients enrolled in COG trials.
Open Researcher and Contributor ID (ORCID)
0000-0001-7737-4324
Areas of Interest
- Clinical Trials Design & Analysis
- Longitudinal Data Analysis
- Survival Analysis
Publications
2024
A subset of image-defined risk factors predict completeness of resection in children with high-risk neuroblastoma: An international multicenter study.
Pediatric blood & cancer.
71(10)
[DOI] 10.1002/pbc.31218.
[PMID] 39072986.
2024
Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology.
Research square.
[DOI] 10.21203/rs.3.rs-4396782/v1.
[PMID] 38883758.
2024
Enrollment on upfront high-risk neuroblastoma trials by race, ethnicity, and poverty status: A report from the Children’s Oncology Group.
Pediatric blood & cancer.
71(7)
[DOI] 10.1002/pbc.31051.
[PMID] 38706187.
2024
Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients with Intermediate-Risk Neuroblastoma: A report from the Children’s Oncology Group study ANBL0531
Journal of Pediatric Surgery.
[DOI] 10.1016/j.jpedsurg.2024.161896.
2024
Healthcare utilization disparities among children with high-risk neuroblastoma treated on Children’s Oncology Group clinical trials.
Pediatric blood & cancer.
71(10)
[DOI] 10.1002/pbc.31192.
[PMID] 38997807.
2024
Late cognitive and adaptive outcomes of patients with neuroblastoma-associated opsoclonus-myoclonus-ataxia-syndrome: A report from the Children’s Oncology Group.
Pediatric blood & cancer.
71(7)
[DOI] 10.1002/pbc.31039.
[PMID] 38689540.
2024
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children’s Oncology Group study ANBL0531.
Pediatric blood & cancer.
71(8)
[DOI] 10.1002/pbc.31089.
[PMID] 38822537.
2023
ANBL1531: The Children’s Oncology Group (COG) Experience Using a Bayesian Approach
Chapter in Broglio, K. & Yu, B. (Eds.), "Case Studies in Innovative Clinical Trials".
19-27
[DOI] 10.1201/9781003288640-2.
2023
Children’s Oncology Group’s 2023 blueprint for research: Neuroblastoma.
Pediatric blood & cancer.
70 Suppl 6(Suppl 6)
[DOI] 10.1002/pbc.30572.
[PMID] 37458162.
2023
Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Pediatric blood & cancer.
70(2)
[DOI] 10.1002/pbc.30054.
[PMID] 36316811.
2023
Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children’s Oncology Group.
Pediatric blood & cancer.
70(8)
[DOI] 10.1002/pbc.30418.
[PMID] 37199022.
2023
Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and withoutMYCNAmplification: A Children’s Oncology Group (COG) Report
Clinical Cancer Research.
29(8):1546-1556
[DOI] 10.1158/1078-0432.ccr-22-3032.
2023
KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children’s Oncology Group.
Journal for immunotherapy of cancer.
11(2)
[DOI] 10.1136/jitc-2022-006530.
[PMID] 36822669.
2023
Persistence of Racial and Ethnic Disparities in Risk and Survival for Patients with Neuroblastoma over Two Decades.
EJC paediatric oncology.
2
[DOI] 10.1016/j.ejcped.2023.100022.
[PMID] 38213818.
2023
Polyclonal Lymphoid Expansion Drives Paraneoplastic Autoimmunity in Neuroblastoma
Cell Reports.
42(8)
[DOI] 10.1016/j.celrep.2023.112879.
[PMID] 37537844.
2023
Statistical Considerations in Pediatric Cancer Trials: Report of American Statistical Association Biopharmaceutical Section Open Forum Discussions
Statistics in Biopharmaceutical Research .
15(4):845-851
[DOI] 10.1080/19466315.2023.2238650.
2023
Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children’s Oncology Group Risk Stratification
Journal of Clinical Oncology.
41(17):3149-3159
[DOI] 10.1200/jco.22.01946.
2023
Topotecan clearance based on a single sample and a population pharmacokinetic model: Application to a pediatric high-risk neuroblastoma clinical trial.
Pediatric blood & cancer.
70(11)
[DOI] 10.1002/pbc.30658.
[PMID] 37664968.
2022
Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy.
Pediatric blood & cancer.
69(9)
[DOI] 10.1002/pbc.29719.
[PMID] 35441784.
2022
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children’s Oncology Group
Journal of Clinical Oncology.
40(35):4107-4118
[DOI] 10.1200/jco.21.02478.
2022
Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Pediatric blood & cancer.
69(9)
[DOI] 10.1002/pbc.29616.
[PMID] 35188340.
2021
A safety and feasibility trial of 131 I-MIBG in newly diagnosed high-risk neuroblastoma: A Children’s Oncology Group study.
Pediatric blood & cancer.
68(10)
[DOI] 10.1002/pbc.29117.
[PMID] 34028986.
2021
Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma.
JAMA network open.
4(7)
[DOI] 10.1001/jamanetworkopen.2021.16248.
[PMID] 34236408.
2021
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
Clinical cancer research : an official journal of the American Association for Cancer Research.
27(8):2179-2189
[DOI] 10.1158/1078-0432.CCR-20-3909.
[PMID] 33504555.
2021
Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children’s Oncology Group Trial ANBL12P1.
Transplantation and cellular therapy.
27(6):490.e1-490.e8
[DOI] 10.1016/j.jtct.2021.03.006.
[PMID] 33823167.
2021
Poverty and Targeted Immunotherapy: Survival in Children’s Oncology Group Clinical Trials for High-Risk Neuroblastoma.
Journal of the National Cancer Institute.
113(3):282-291
[DOI] 10.1093/jnci/djaa107.
[PMID] 33227816.
2021
Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group
JCO Clinical Cancer Informatics.
(5):1181-1188
[DOI] 10.1200/cci.21.00103.
2021
Revised Neuroblastoma Risk Classification System: A Report From the Children’s Oncology Group
Journal of Clinical Oncology.
39(29):3229-3241
[DOI] 10.1200/jco.21.00278.
2021
Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children’s Oncology Group.
The American journal of surgical pathology.
45(8):1075-1081
[DOI] 10.1097/PAS.0000000000001647.
[PMID] 33739795.
2020
Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
38(17):1906-1918
[DOI] 10.1200/JCO.19.03285.
[PMID] 32315273.
2020
Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children’s Oncology Group.
European journal of cancer (Oxford, England : 1990).
133:112-119
[DOI] 10.1016/j.ejca.2020.04.007.
[PMID] 32492633.
2020
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children’s Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
38(19):2160-2169
[DOI] 10.1200/JCO.20.00203.
[PMID] 32343642.
2020
MYCN amplification and ATRX mutations are incompatible in neuroblastoma.
Nature communications.
11(1)
[DOI] 10.1038/s41467-020-14682-6.
[PMID] 32060267.
2020
Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations.
Nature communications.
11(1)
[DOI] 10.1038/s41467-020-18987-4.
[PMID] 33056981.
2020
Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children’s Oncology Group ANBL0532 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
38(24):2741-2752
[DOI] 10.1200/JCO.19.03316.
[PMID] 32530765.
2020
Reply to K. Beiske et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
38(31):3720-3721
[DOI] 10.1200/JCO.20.02147.
[PMID] 32931402.
2020
Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future
JCO Clinical Cancer Informatics.
(4):895-905
[DOI] 10.1200/cci.20.00074.
2020
The ganglioside GD2 as a circulating tumor biomarker for neuroblastoma.
Pediatric blood & cancer.
67(1)
[DOI] 10.1002/pbc.28031.
[PMID] 31612589.
2019
Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children’s Oncology Group Phase II Study.
Clinical cancer research : an official journal of the American Association for Cancer Research.
25(20):6044-6051
[DOI] 10.1158/1078-0432.CCR-19-0798.
[PMID] 31358541.
2019
Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children’s Oncology Group Study ANBL0531.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
37(2):115-124
[DOI] 10.1200/JCO.18.00419.
[PMID] 30444686.
2019
Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.
JAMA.
322(8):746-755
[DOI] 10.1001/jama.2019.11642.
[PMID] 31454045.
2019
Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children’s Oncology Group Study ANBL0531.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
37(34):3243-3255
[DOI] 10.1200/JCO.19.00919.
[PMID] 31386611.
2019
Neuroblastoma in relation to joint effects of vitamin A and maternal and offspring variants in vitamin A-related genes: A report of the Children’s Oncology Group.
Cancer epidemiology.
61:165-171
[DOI] 10.1016/j.canep.2019.06.009.
[PMID] 31279991.
2019
Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children’s Oncology Group (COG).
European journal of cancer (Oxford, England : 1990).
112:66-79
[DOI] 10.1016/j.ejca.2019.02.003.
[PMID] 30947024.
2019
Prevalence and Clinical Correlations of Somatostatin Receptor-2 (SSTR2) Expression in Neuroblastoma.
Journal of pediatric hematology/oncology.
41(3):222-227
[DOI] 10.1097/MPH.0000000000001326.
[PMID] 30334904.
2019
Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms’ tumor.
JCI insight.
4(15)
[DOI] 10.1172/jci.insight.127098.
[PMID] 31391345.
2018
A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931.
Frontiers in immunology.
9
[DOI] 10.3389/fimmu.2018.01355.
[PMID] 29967609.
2018
Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931.
Frontiers in immunology.
9
[DOI] 10.3389/fimmu.2018.01641.
[PMID] 30046297.
2018
Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.
The Lancet. Child & adolescent health.
2(1):25-34
[DOI] 10.1016/S2352-4642(17)30130-X.
[PMID] 29376112.
2018
MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children’s oncology group.
Oncotarget.
9(5):6416-6432
[DOI] 10.18632/oncotarget.23740.
[PMID] 29464082.
2018
Neuroblastoma Patients’ KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children’s Oncology Group.
Clinical cancer research : an official journal of the American Association for Cancer Research.
24(1):189-196
[DOI] 10.1158/1078-0432.CCR-17-1767.
[PMID] 28972044.
2018
Statistical Framework in Support of a Revised Children’s Oncology Group Neuroblastoma Risk Classification System.
JCO clinical cancer informatics.
2:1-15
[DOI] 10.1200/CCI.17.00140.
[PMID] 30652588.
2018
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children’s Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
59(3):502-508
[DOI] 10.2967/jnumed.117.195883.
[PMID] 28887399.
2018
Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.
European journal of nuclear medicine and molecular imaging.
45(2):292-305
[DOI] 10.1007/s00259-017-3829-7.
[PMID] 28940046.
2017
Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children’s Oncology Group.
Cancer.
123(21):4224-4235
[DOI] 10.1002/cncr.30873.
[PMID] 28696504.
2017
Historical Time to Disease Progression and Progression-Free Survival in Patients With Recurrent/Refractory Neuroblastoma Treated in the Modern Era on Children’s Oncology Group Early-Phase Trials
Cancer.
123(24):4914-4923
[DOI] 10.1002/cncr.31037.
2017
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials.
Cancer.
123(24):4914-4923
[DOI] 10.1002/cncr.30934.
[PMID] 28885700.
2017
HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.
Frontiers in immunology.
8
[DOI] 10.3389/fimmu.2017.00675.
[PMID] 28659916.
2017
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
The Lancet. Oncology.
18(7):946-957
[DOI] 10.1016/S1470-2045(17)30355-8.
[PMID] 28549783.
2017
MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children’s Oncology Group.
Pediatric blood & cancer.
64(11)
[DOI] 10.1002/pbc.26545.
[PMID] 28383813.
2017
Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.
European journal of cancer (Oxford, England : 1990).
72:177-185
[DOI] 10.1016/j.ejca.2016.11.022.
[PMID] 28033528.
2016
A family-based study of gene variants and maternal folate and choline in neuroblastoma: a report from the Children’s Oncology Group.
Cancer causes & control : CCC.
27(10):1209-18
[DOI] 10.1007/s10552-016-0799-1.
[PMID] 27541142.
2016
Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
34(7):740-6
[DOI] 10.1200/JCO.2015.63.2042.
[PMID] 26755515.
2016
Erratum to: Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children’s Oncology Group.
European journal of nuclear medicine and molecular imaging.
43(7)
[PMID] 27044383.
2016
Neuropeptide Y as a Biomarker and Therapeutic Target for Neuroblastoma.
The American journal of pathology.
186(11):3040-3053
[DOI] 10.1016/j.ajpath.2016.07.019.
[PMID] 27743558.
2016
Surgical protocol violations in children with renal tumors provides an opportunity to improve pediatric cancer care: a report from the Children’s Oncology Group.
Pediatric blood & cancer.
63(11):1905-10
[DOI] 10.1002/pbc.26083.
[PMID] 27229358.
2016
Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children’s Oncology Group.
European journal of nuclear medicine and molecular imaging.
43(3):474-481
[DOI] 10.1007/s00259-015-3179-2.
[PMID] 26338179.
2015
Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children’s Oncology Group study.
British journal of cancer.
113(1):57-63
[DOI] 10.1038/bjc.2015.188.
[PMID] 26035700.
2015
Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children’s Oncology Group study AREN03B2.
Cancer.
121(14):2457-64
[DOI] 10.1002/cncr.29368.
[PMID] 25845370.
2015
Comparison of diagnostic performance of CT and MRI for abdominal staging of pediatric renal tumors: a report from the Children’s Oncology Group.
Pediatric radiology.
45(2):166-72
[DOI] 10.1007/s00247-014-3138-2.
[PMID] 25135711.
2015
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.
Nature genetics.
47(8):864-71
[DOI] 10.1038/ng.3333.
[PMID] 26121087.
2014
Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children’s Oncology Group.
Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.
17(6):441-9
[DOI] 10.2350/14-06-1505-OA.1.
[PMID] 25207821.
2014
Clear cell sarcoma of the kidney demonstrates an embryonic signature indicative of a primitive nephrogenic origin.
Genes, chromosomes & cancer.
53(5):381-91
[DOI] 10.1002/gcc.22149.
[PMID] 24488803.
2014
Feasibility of using CT volume as a predictor of specimen weight in a subgroup of patients with low risk Wilms tumors registered on COG Study AREN03B2: implications for central venous catheter placement.
Journal of pediatric urology.
10(5):969-73
[DOI] 10.1016/j.jpurol.2014.02.006.
[PMID] 24863984.
2014
Inter-rater reliability of surgical reviews for AREN03B2: a COG renal tumor committee study.
Journal of pediatric surgery.
49(1):154-8; discussion 158
[DOI] 10.1016/j.jpedsurg.2013.09.047.
[PMID] 24439601.
2014
Race disparities in peptide profiles of North American and Kenyan Wilms tumor specimens.
Journal of the American College of Surgeons.
218(4):707-20
[DOI] 10.1016/j.jamcollsurg.2013.12.044.
[PMID] 24655859.
2013
A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children’s Oncology Group study ANBL00P1.
Bone marrow transplantation.
48(7):947-52
[DOI] 10.1038/bmt.2012.276.
[PMID] 23334272.
2013
Children’s Oncology Group’s 2013 blueprint for research: renal tumors.
Pediatric blood & cancer.
60(6):994-1000
[DOI] 10.1002/pbc.24419.
[PMID] 23255438.
2013
Detection of preoperative wilms tumor rupture with CT: a report from the Children’s Oncology Group.
Radiology.
266(2):610-7
[DOI] 10.1148/radiol.12120670.
[PMID] 23192775.
2013
Extending the State-Space Model To Accommodate Missing Values in Responses and Covariates
Journal of the American Statistical Association.
108(501):202-216
[DOI] 10.1080/01621459.2012.746066.
2013
Mentoring in pediatric oncology: a report from the Children’s Oncology Group Young Investigator Committee.
Journal of pediatric hematology/oncology.
35(6):456-61
[DOI] 10.1097/MPH.0b013e31829eec33.
[PMID] 23892351.
2013
Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children’s Oncology Group.
Cancer.
119(20):3718-26
[DOI] 10.1002/cncr.28251.
[PMID] 23901000.
2013
Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children’s Oncology Group and the International Neuroblastoma Pathology Committee.
Pediatric blood & cancer.
60(3):363-70
[DOI] 10.1002/pbc.24238.
[PMID] 22744966.
2013
Primary nephrectomy and intraoperative tumor spill: report from the Children’s Oncology Group (COG) renal tumors committee.
Journal of pediatric surgery.
48(1):34-8
[DOI] 10.1016/j.jpedsurg.2012.10.015.
[PMID] 23331790.
2013
Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s oncology group.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
54(4):541-8
[DOI] 10.2967/jnumed.112.112334.
[PMID] 23440556.
2012
A genome-wide association study identifies susceptibility loci for Wilms tumor.
Nature genetics.
44(6):681-4
[DOI] 10.1038/ng.2251.
[PMID] 22544364.
2012
A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children’s Oncology Group study.
Annals of surgery.
256(4):573-80
[PMID] 22964741.
2012
Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children’s Oncology Group.
International journal of molecular imaging.
2012
[DOI] 10.1155/2012/250834.
[PMID] 23050139.
2012
Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in a cooperative group setting: a Pediatric Oncology Group study: a report from the Children’s Oncology Group.
Pediatric blood & cancer.
59(5):902-7
[DOI] 10.1002/pbc.24207.
[PMID] 22744917.
2012
Reducing developmental risk for emotional/behavioral problems: a randomized controlled trial examining the Tools for Getting Along curriculum.
Journal of school psychology.
50(2):149-66
[DOI] 10.1016/j.jsp.2011.09.003.
[PMID] 22386118.
2012
Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastoma.
Cancer research.
72(18):4714-23
[DOI] 10.1158/0008-5472.CAN-12-0886.
[PMID] 22815530.
2011
CASZ1b, the short isoform of CASZ1 gene, coexpresses with CASZ1a during neurogenesis and suppresses neuroblastoma cell growth.
PloS one.
6(4)
[DOI] 10.1371/journal.pone.0018557.
[PMID] 21490919.
2011
Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children’s Oncology Group.
Pediatric blood & cancer.
56(7):1041-5
[DOI] 10.1002/pbc.22991.
[PMID] 21328522.
2011
miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples.
Clinical cancer research : an official journal of the American Association for Cancer Research.
17(24):7684-92
[DOI] 10.1158/1078-0432.CCR-11-0610.
[PMID] 22031095.
2011
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children’s Oncology Group.
Clinical cancer research : an official journal of the American Association for Cancer Research.
17(21):6858-66
[DOI] 10.1158/1078-0432.CCR-11-0995.
[PMID] 21908574.
2011
Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children’s Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
29(33):4351-7
[DOI] 10.1200/JCO.2010.34.3293.
[PMID] 22010014.
2009
Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG.
Pediatric blood & cancer.
53(4):563-9
[DOI] 10.1002/pbc.22106.
[PMID] 19530234.
2009
Establishment of a pediatric liver transplantation program: experience with 100 transplantation procedures.
Transplantation proceedings.
41(6):2444-6
[DOI] 10.1016/j.transproceed.2009.06.072.
[PMID] 19715946.
2009
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.
The Lancet. Oncology.
10(7):663-71
[DOI] 10.1016/S1470-2045(09)70154-8.
[PMID] 19515614.
2005
High Sensitivity C-Reactive Protein in Systemic Lupus Erythematosus: Relation to Disease Activity
Lupus.
14(8):576-582
2003
Inferences About the Scale Parameter of the Gamma Distribution Based on Data Mixed from Censoring and Grouping
Statistics & Probability Letters.
62:229-243
2002
Testing the Mean of Skewed Distributions: Chen’s t2 Test Revisited
.
18(2):213-224
Grants
Mar 2023
ACTIVE
Children's Oncology Group Statistics and Data Center
Role: Principal Investigator
Funding: UNIV OF SOUTHERN CALIFORNIA
via NATL INST OF HLTH NCI
Sep 2022
ACTIVE
Comprehensive Evaluation of Immune Function in Patients Receiving Multimodal Therapy for High-Risk Neuroblastoma
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via US ARMY MED RES ACQUISITION
Mar 2022
– Sep 2023
Novel Health Equity Intervention to Improve Pediatric Oncology Outcome Disparities: Targeting Poverty and Psychosocial Stress
Role: Principal Investigator
Funding: DANA FARBER CANCER INST
via NATL INST OF HLTH NCI
Jan 2022
ACTIVE
Statistical Support for COG Neuroblastoma Projects
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
Sep 2021
ACTIVE
Robust assays to define telomere maintenance mechanisms as cancer biomarkers
Role: Principal Investigator
Funding: TEXAS TECH UNIV HLTH SCIENCES CENTER
via NATL INST OF HLTH NCI
Jun 2021
– Jul 2022
Alternate telomere maintenance mechanisms in high-risk neuroblastoma as prognostic indicators and therapeutic targets
Role: Principal Investigator
Funding: TEXAS TECH UNIV HLTH SCIENCES CENTER
via NATL INST OF HLTH NCI
Dec 2020
ACTIVE
Integration of Lorlatinib to improve outcomes for patients with high-risk ALK-driven neuroblastoma: A COG and SIOPEN/Gustave Roussy international collaboration
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via SOLVING KIDS' CANCER
Sep 2020
ACTIVE
Characterizing tumor evolution and therapy resistance in high-risk neuroblastoma
Role: Principal Investigator
Funding: DANA FARBER CANCER INST
via US ARMY MED RES ACQUISITION
Aug 2020
– Jul 2022
Statistical analysis for COG Neuroblastoma Committee projects
Role: Principal Investigator
Funding: UNIV OF CHICAGO
Apr 2020
ACTIVE
Project A: Biomarkers to Guide Therapy Selection in Children with High-Risk Neuroblastoma
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
Apr 2020
ACTIVE
Project B: Biomarkers to Guide Therapy Selection in Children with High-Risk Neuroblastoma
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
Aug 2019
– Jul 2024
Statistical Analysis for COG Neuroblastoma Committee Projects
Role: Principal Investigator
Funding: SEATTLE CHILDRENS HOSPITAL
Apr 2019
– Feb 2023
Children's Oncology Group Statistics and Data Center
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via NATL INST OF HLTH NCI
Mar 2019
– Jun 2021
Molecular assays defining telomere lengthening mechanisms (TLM) as neuroblastoma prognostic markers for potential integration into a revised COG neuroblastoma risk classifier
Role: Principal Investigator
Funding: TEXAS TECH UNIV HLTH SCIENCES CENTER
via NATL INST OF HLTH NCI
Apr 2018
– Mar 2022
Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma
Role: Principal Investigator
Funding: DANA FARBER CANCER INST
via NATL INST OF HLTH NCI
Apr 2018
– Aug 2024
DISCOVERING MECHANISMS OF NEUROBLASTOMA TUMORIGENESIS TO IMPROVE PATIENT OUTCOMES
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
Dec 2017
– Nov 2020
Genomic and functional characterization of a panel of neuroblastoma patient-derived xenografts and cell lines
Role: Principal Investigator
Funding: TEXAS TECH UNIV HLTH SCIENCES CENTER
via NATL INST OF HLTH NCI
Jul 2015
– Jun 2021
Late Effects after High Risk Neuroblastoma – The Leahrn Study Y
Role: Principal Investigator
Funding: UNIV OF CHICAGO
via ST BALDRICKS FOUNDATION
Apr 2015
– Mar 2018
The Genetic Basis of Neuroblastoma Tumorigenesis (GWAS)
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
Mar 2015
– Feb 2017
Molecular Diagnostics for Risk Stratification and Monitoring of Neuroblastoma
Role: Principal Investigator
Funding: CHILDRENS HOSP LOS ANGELES
via NATL INST OF HLTH NCI
Aug 2014
– Jul 2017
Isotretinoin Pharmacokinetics and Pharmacogenomics in High Risk Neuroblastoma
Role: Principal Investigator
Funding: TEXAS TECH UNIV
via NATL INST OF HLTH
Mar 2014
– Feb 2019
Children's Oncology Group Statistics and Data Center
Role: Project Manager
Funding: NATL INST OF HLTH NCI
Jul 2013
– Jun 2016
The Interactive International Neuroblastoma Risk Group Database
Role: Principal Investigator
Funding: UNIV OF CHICAGO
via ST BALDRICKS FOUNDATION
Education
Ph.D., Statistics
2002-2007
·
University of Florida
M.S., Statistics
2000-2002
·
Florida International University
B.S., Mathematical Sciences
1996-2000
·
Florida International University
Contact Details
Phones:
- Business:
- (352) 273-0577
Emails:
- Business:
- anaranjo@cog.ufl.edu
Addresses:
- Business Mailing:
-
6011 NW 1ST PL STE 10
GAINESVILLE FL 32607 - Business Street:
-
6011 NW 1ST PL STE 10
GAINESVILLE FL 32607